Literature DB >> 22182956

Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding.

Payal Kohli1, Christopher P Cannon.   

Abstract

Major advances in the diagnosis of acute coronary syndromes (ACS) have occurred in 2011, but physicians treating ACS still walk the tightrope between efficacy and bleeding. Key publications have shed light on this delicate balance and heralded a new era of novel oral anticoagulants for the treatment of ACS.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22182956     DOI： 10.1038/nrcardio.2011.206

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  8 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

3.  Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Authors:  Jessica L Mega; Willibald Hochholzer; Andrew L Frelinger; Michael J Kluk; Dominick J Angiolillo; Dean J Kereiakes; Steven Isserman; William J Rogers; Christian T Ruff; Charles Contant; Michael J Pencina; Benjamin M Scirica; Janina A Longtine; Alan D Michelson; Marc S Sabatine
Journal:  JAMA       Date:  2011-11-16       Impact factor: 56.272

4.  Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome.

Authors:  Nicholas L Mills; Antonia M D Churchhouse; Kuan Ken Lee; Atul Anand; David Gamble; Anoop S V Shah; Elspeth Paterson; Margaret MacLeod; Catriona Graham; Simon Walker; Martin A Denvir; Keith A A Fox; David E Newby
Journal:  JAMA       Date:  2011-03-23       Impact factor: 56.272

5.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Authors:  Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

6.  In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™.

Authors:  Robin Mathews; Eric D Peterson; Anita Y Chen; Tracy Y Wang; Chee Tang Chin; Gregg C Fonarow; Christopher P Cannon; John S Rumsfeld; Matthew T Roe; Karen P Alexander
Journal:  Am J Cardiol       Date:  2011-02-15       Impact factor: 2.778

7.  Apixaban with antiplatelet therapy after acute coronary syndrome.

Authors:  John H Alexander; Renato D Lopes; Stefan James; Rakhi Kilaru; Yaohua He; Puneet Mohan; Deepak L Bhatt; Shaun Goodman; Freek W Verheugt; Marcus Flather; Kurt Huber; Danny Liaw; Steen E Husted; Jose Lopez-Sendon; Raffaele De Caterina; Petr Jansky; Harald Darius; Dragos Vinereanu; Jan H Cornel; Frank Cools; Dan Atar; Jose Luis Leiva-Pons; Matyas Keltai; Hisao Ogawa; Prem Pais; Alexander Parkhomenko; Witold Ruzyllo; Rafael Diaz; Harvey White; Mikhail Ruda; Margarida Geraldes; Jack Lawrence; Robert A Harrington; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-07-24       Impact factor: 91.245

8.  RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.

Authors:  Ph Gabriel Steg; Shamir R Mehta; J Wouter Jukema; Gregory Y H Lip; C Michael Gibson; Frantisek Kovar; Petr Kala; Alberto Garcia-Hernandez; Ronny W Renfurm; Christopher B Granger
Journal:  Eur Heart J       Date:  2011-08-30       Impact factor: 29.983
  8 in total
  2 in total

1.  Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome.

Authors:  Lin Liu; Huocheng Liao; Sigan Zhong; Yan Liu; Chun Xiao
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

2.  Association of QRS Complex Fragmentation with QT Interval Prolongation in Patients with Ischemic Heart Disease.

Authors:  N J Aquino; O A Centurión; J M Torales; L M Miño; K E Scavenius; J F Alderete; J C Candia; L B García; C Cáceres; J E Martínez; O A Lovera
Journal:  Curr Health Sci J       Date:  2019-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.